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Abstract
Background: Selenium (Se) is an essential trace element with antioxidant, anti-inflammatory, and immunomodulatory
effects. So far, several randomized clinical trials (RCTs) have demonstrated that parenteral Se may improve clinical
outcomes in intensive care unit (ICU) patients. Since publication of our previous systematic review and meta-analysis
on antioxidants in the ICU, reports of several trials have been published, including the largest RCT on Se therapy. The
purpose of the present systematic review was to update our previous data on intravenous (IV) Se in the critically ill.
Methods: We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. We included RCTs
with parallel groups comparing parenteral Se as single or combined therapy with placebo. Potential trials were
evaluated according to specific eligibility criteria, and two reviewers abstracted data from original trials in duplicate
independently. Overall mortality was the primary outcome; secondary outcomes were infections, ICU length of stay
(LOS), hospital LOS, ventilator days, and new renal dysfunction.
Results: A total of 21 RCTs met our inclusion criteria. When the data from these trials were aggregated, IV Se had
no effect on mortality (risk ratio [RR] 0.98, 95 % CI 0.90–1.08, P = 0.72, heterogeneity I2 = 0 %). In addition, when the
results of ten trials in which researchers reported on infections were statistically aggregated, there was no significant
treatment effect of parenteral Se (RR 0.95, 95 % CI 0.88–1.02, P = 0.15, I2 = 0 %). There was no positive or negative effect
of Se therapy on ICU and hospital LOS, renal function, or ventilator days.
Conclusions: In critically ill patients, IV Se as monotherapy does not improve clinical outcomes.
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Background
Selenium (Se) is an essential trace element with anti-
inflammatory and immunomodulatory properties, and it
is currently considered the cornerstone of the antioxi-
dant defense system [1, 2]. Over the past 30 years, a
large number of basic and clinical studies have revealed
the crucial role of Se in the maintenance of immune,
metabolic, endocrine, and cellular homeostasis, which is
attributed to its presence in selenoproteins, as the 21st
amino acid selenocysteine [3]. These selenoenzymes are
involved in redox signaling, antioxidant defense, thyroid
hormone metabolism, and immune responses [4]. Thus
far, critical illness with systemic inflammation and
multiple organ dysfunction syndrome was deemed to be
associated with an early reduction in plasma/serum Se
and glutathione peroxidase (GPx) activity, where both
parameters correlate inversely with the severity of illness
and clinical outcome [5, 6].
Over the last two decades, researchers in several ran-
domized clinical trials (RCTs) have evaluated the role of
parenteral inorganic selenocompounds such as sodium
selenite or selenious acid, either as a single-agent strat-
egy or in combination with other antioxidant micronu-
trients (antioxidant cocktails) and using different dose
regimens in critically ill patients with systemic inflam-
mation. These studies have shown beneficial results in
terms of reduction of infections, mortality, and other
relevant clinical outcomes in the critically ill.
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In 2005, the authors of the first comprehensive system-
atic review and meta-analysis on antioxidant nutrients in
the critically ill [7] demonstrated that Se supplementation
could be associated with a reduction in mortality, while
nonselenium antioxidants had no effect on mortality.
More recently, authors of other systematic reviews and
meta-analyses [8–14] on Se therapy in intensive care unit
(ICU) patients found that pharmaconutrition with paren-
teral Se monotherapy may be able to significantly reduce
mortality in patients with sepsis, particularly when an
intravenous (IV) bolus was provided and daily doses
higher than 500 μg were administered. In addition, Se sub-
stitution was more effective in those patients with higher
risk of death [13].
Nonetheless, since 2013, several studies of the effects
of parenteral Se supplementation as single or combined
therapy have been published [7, 14–17]. The REducing
Deaths due to Oxidative Stress (REDOXS) trial [16]
investigators were unable to find a therapeutic benefit of
a combined Se supplementation regimen (300 μg enteral
plus 500 μg parenteral). The most recent and largest
RCT on Se monotherapy in severe sepsis and septic
shock, the Sodium Selenite and Procalcitonin Guided
Antimicrobial Therapy in Severe Sepsis (SISPCT) study
[17], further demonstrated that high-dose IV sodium
selenite was not associated with improved survival.
Therefore, with the aim of elucidating the overall effi-
cacy of parenteral Se as single or combined therapy
(antioxidant cocktails) in adult critically ill patients, we
performed an update of our previous systematic review
and meta-analysis of the literature.
Methods
Study identification
We conducted a systematic review of the literature pub-
lished between 1980 and 2015 using the computerized da-
tabases of MEDLINE, Embase, the Cochrane Controlled
Trials Register, and the Cochrane Database of Systematic
Reviews. Text words or MeSH headings containing
“randomized,” “blind,” “clinical trial,” “parenteral,” “intra-
venous,” “selenium,” “sodium selenite,” “selenious acid,”
“antioxidant cocktails,” “critical illness,” and “critically ill”
were used without any language restriction. We also
reviewed our personal files and comprehensive reviews for
additional original studies.
Study selection criteria
Original studies were included if they met the following
criteria:
1. Randomized controlled trial study design with a
parallel group
2. A population of critically ill adult patients (>18 years
old), defined as patients admitted to an ICU (If the
study population was unclear, we considered a
mortality rate higher than 5 % in the control group
to be consistent with critical illness.)
3. The administration of parenteral Se in the
intervention arm (either with or without an initial
bolus) as a single-agent strategy or in combination
with other antioxidant micronutrients compared
with a control group with a placebo
4. The evaluation of clinically relevant outcomes such as
mortality, infectious complications, ICU or hospital
length of stay (LOS), length of mechanical ventilation
(MV), and new renal dysfunction including the
requirement of renal replacement therapy
Clinical studies that reported only biochemical, meta-
bolic, or immunologic results were excluded.
All original studies were evaluated and abstracted in
duplicate independently by two reviewers using a data ab-
straction form that had been used previously [18]. A
discussion was held and consensus was obtained between
the reviewers when a disagreement occurred. When
additional data were needed, we attempted to contact the
authors of the published article. We scored the methodo-
logical quality of the original trials, aiming to obtain a
score between 0 and 14, with the following high-quality
criteria: (1) the extent to which randomization was
concealed, (2) intention-to-treat (ITT)-based analysis, (3)
extent of blinding, (4) baseline comparability of groups,
(5) extent of follow-up, (6) description of treatment proto-
cols and cointerventions in both arms, and (7) definition
of clinical outcomes [18].
We designated studies as level I if all of the following
criteria were fulfilled: concealed randomization, blinded
outcome adjudication, and an ITT analysis, which are
the strongest methodological tools to reduce bias. A
study was considered as level II if any one of the above-
described characteristics was unfulfilled.
Data analysis
The primary outcome was overall mortality. Hospital
mortality, when available, was used for the statistical
analysis. If not reported, we used ICU mortality or 28-
day mortality. When not specified, mortality was as-
sumed to be hospital mortality. Secondary outcomes
included infections, hospital and ICU LOS, MV days,
and new renal dysfunction as defined by the authors of
the original articles. We used the definition of infections
employed by each author. The data from all trials report-
ing the specific outcome were combined to calculate the
pooled risk ratio (RR) for mortality and infections, and
pooled weighted mean difference (WMD) for LOS, both
with 95 % CIs. All analyses were conducted using
Review Manager (RevMan) 5.3 software, except for the
test for asymmetry. Pooled RRs were calculated using
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the Mantel-Haenszel estimator, and WMDs were esti-
mated by the inverse variance approach. The random ef-
fects model of DerSimonian and Laird [19] was used to
estimate variances for the Mantel-Haenszel and inverse
variance estimators. When possible, studies were aggre-
gated on an ITT basis. Heterogeneity in the data was
tested by a weighted Mantel-Haenszel chi-square test
and quantified by using the I2 statistics implemented in
RevMan 5.3 software. Differences between subgroups
were analyzed using the test of subgroup differences
described by Deeks et al. [20], and the results were
expressed using the P values. Funnel plots were gener-
ated to assess the possibility of publication bias, and the
Egger regression test was used to measure funnel
plot asymmetry [21]. Asymmetry was calculated using
Comprehensive Meta-Analysis 3.0 statistical software
(Biostat Inc., Englewood, NJ, USA). P values <0.05 and
<0.10 were considered as statistically significant and indi-
cators of a trend, respectively.
A priori hypothesis testing
Significant differences in the protocols of the original stud-
ies were expected. Thus, several prespecified hypothesis-
generating subgroup analyses were performed to identify
potentially more beneficial treatment strategies. First, we
compared the results of trials in which investigators ad-
ministered parenteral Se as monotherapy with studies in
which researchers provided parenteral Se in antioxidant
cocktails. Based on previous RCTs showing a beneficial ef-
fect of an initial loading dose, those RCTs using an initial
loading dose as an IV bolus of Se were then compared with
trials those that did not. In addition, because researchers in
previous trials found that daily doses higher than 500 μg
were associated with better outcomes, we compared the re-
sults between three subgroups having different daily doses:
lower than 500 μg, equal to 500 μg, and greater than
500 μg. Moreover, on the basis of a possibly larger treat-
ment effect in patients with higher risk of death, we com-
pared studies including patients with higher mortality vs.
those with lower mortality. Mortality was considered to be
high or low based on whether it was greater or less than
the mean control group mortality of all the trials. Addition-
ally, we postulated that trials with lower quality (level II
studies) might demonstrate a greater treatment effect than
those trials with higher quality (level I studies). Further-
more, as current evidence showed benefits in terms of re-
duction in mortality in septic patients, the results of RCTs
performed only with patients with sepsis were compared
with RCTs performed with heterogeneous patient popula-
tions (nonsepsis studies). We also assessed the effect of Se
in soils according to the geographical region where the trial
was conducted. For this purpose, we compared RCTs per-
formed in deprived regions (Europe, South America, and
Asia) versus trials performed in nondeprived regions
(North America). Finally, given the interaction between Se
and procalcitonin (PCT) in the SISPCT study [17], we con-
ducted a sensitivity analysis excluding the PCT guidance
group of patients.
Results
Study identification and selection
A total of 41 relevant citations were identified in the
search of computerized bibliographic databases and a re-
view of reference lists in related articles. Of these, we ex-
cluded 20 for the following reasons: 8 trials did not
include ICU patients (mostly surgery patients) [22–29]; 1
study did not evaluate clinical outcomes [30]; 1 study
compared high-dose with low-dose Se [31]; 3 articles were
duplicates [32–34]; 4 articles were systematic reviews; 1
trial was published as an abstract [35], and we were unable
to obtain the data from the authors to complete our data
abstraction process; 1 study was not an RCT [36]; and in 1
trial Se was not given intravenously [37].
Ultimately, 21 studies [14–17, 38–54] met our inclu-
sion criteria and were included; they comprised a total
of 4044 patients (Tables 1 and 2). The reviewers reached
100 % agreement for the inclusion of the trials. The
mean methodological score of all trials was 9 of a max-
imum possible score of 14 (range 4–13). Randomization
was concealed in 9 (43 %) of 21 trials; ITT analysis was
performed in 14 (67 %) of 21 trials; and double-blinding
was done in 7 (33 %) of 21 of the studies. There were 6
level I studies and 15 level II studies. The details of the
methodological quality of the individual trials are shown
in Table 1.
Primary outcome: mortality
When the results of the 21 trials in which researchers re-
ported mortality were aggregated, no statistically significant
difference was found between Se supplementation and pla-
cebo (RR 0.98, 95 % CI 0.90–1.08, P = 0.72, heterogeneity
I2 = 0 %) (Fig. 1). In the sensitivity analysis, after excluding
the PCT guidance group of the Bloos et al. study, we found
that the new RR was 0.95 (95 % CI 0.79–1.15, P = 0.63,
I2 = 35 %) (Additional file 1: Figure S1).
Secondary outcomes
Overall effect on new infectious complications
When data from ten studies were included in the meta-
analysis, no significant effect of Se supplementation
on infections was found (RR 0.95, 95 % CI 0.88–1.02,
P = 0.15, I2 = 0 %) (Fig. 2).
Overall effect on ICU and hospital length of stay and
ventilator days
When ten RCTs in which researchers reported ICU LOS
were statistically aggregated, there were no significant dif-
ferences between the groups (WMD 0.32, 95 % CI −0.80
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Table 1 Randomized clinical trials evaluating selenium supplementation in critically ill patients
Study Population Methodology (score) Intervention
Kuklinski 1991 [38] Patients with acute pancreatic necrosis C.Random: not sure PN+ selenium supplementation (500 μg/day)
vs. PN without selenium supplementation
n = 17 ITT: no
Blinding: no
(4)
Zimmerman 1997 [39] Patients with SIRS, sepsis, APACHE II score
>15, and multiorgan failure score >6
C.Random: no IV selenium as sodium selenite 1000 μg as a
bolus and then 1000 μg sodium selenite
24 h as a continuous infusion over 28 days
vs. standardn = 40 ITT: yes
Blinding: no
(6)
Berger 1998 [40] Burns >30 % TBSA C.Random: yes IV copper (40.4 μmol), selenium (159 μg),
zinc (406 μmol) + standard trace elements
vs. standard trace elements (copper
20 μmol, selenium 32 μg, zinc 100 μmol)
from days 0 to 8, all received early EN
n = 20 ITT: yes
Blinding: double blind
(12)
Angstwurm 1999 [41] Patients with SIRS and sepsis at 11 ICUs C.Random: not sure PN with high-dose selenium (535 μg ×
3 days, 285 μg × 3 days, 155 μg × 3 days,
and 35 μg thereafter) vs. low-dose selenium
(35 μg/day for duration of study)
n = 42 ITT: yes
Blinding: no
(10)
Porter 1999 [42] Surgical ICU penetrating trauma patients
with Injury Severity Score ≥25
C.Random: yes 50 μg selenium IV every 6 h + 400 IU
vitamin E, 100 mg vitamin C every 8 h, and
8 g of N-acetylcysteine every 6 h via
nasogastric or oral route from days 0 to 7
vs. none
n = 18 ITT: yes
Blinding: no
(9)
Berger 2001 [43] Trauma patients, surgical ICU C.Random: yes IV selenium supplementation (500 μg/day)
vs. placebo (selenium group randomized
further to two groups: 500 μg selenium alone
vs. 500 μg selenium+ 150 mg α-tocopherol +
13 mg zinc) given slowly for first 5 days after
injury (all groups received EN)
n = 31 ITT: no
Blinding: double
(9)
Lindner 2004 [44] Patients with acute pancreatitis admitted to
the ICU
C.Random: not sure IV sodium selenite dose of 2000 μg on day
1, 1000 μg on days 2–5, and 300 μg from
day 6 until discharge vs. placebo (isotonic
0.9 % IV NaCl solution)n = 70 ITT: no
Blinding: single
(9)
Angstwurm 2007 [45] Multicenter mixed ICUs C.Random: not sure 1000 μg selenium IV within 1 h followed by
1000 μg selenium for 14 days vs. NaCl
(0.9 %) (all patients received EN or PN)n = 249 ITT: no
Blinding: double
(8)
Berger 2007 [46] Burns >20 % TBSA C.Random: not sure IV 100 ml of copper (59 μmol) + selenium
(375 μg + zinc (574 μmol) vs. NaCl (0.9 %)
from admission for 5–15 days
n = 21 ITT: yes Both groups were on EN
Blinding: no
(8)
Forceville 2007 [47] Septic shock patients C.Random: not sure 4000 μg selenium IV on day 1 followed by
1000 μg selenium for 9 days vs. NaCl (0.9 %)
(all patients received EN or PN)n = 60 ITT: no
Blinding: double
(8)
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Table 1 Randomized clinical trials evaluating selenium supplementation in critically ill patients (Continued)
Mishra 2007 [48] Septic ICU patients C.Random: not sure 474 μg selenium IV × 3 days followed by
316 μg × 3 days, 158 μg × 3 days, and
31.6 μg thereafter vs. 31.6 μg selenium
(all patients received EN or PN)
n = 40 ITT: yes
Blinding: double
(9)
Berger 2008 [49] Mixed ICU C.Random: not sure IV selenium supplementation loading dose
540 μg/day + zinc (60 mg) + vitamin C
2700 mg + vitamin B 305 mg + vitamin E
enteral 600 mg + vitamin E 12.8 mg IV for
2 days followed by half the dose of all vs.
standard vitamins
n = 200 ITT: yes
Blinding: no All groups received EN or PN
(10)
El-Attar 2009 [50] Patients with COPD C.Random: yes IV selenium as sodium selenite 100 μg/day,
zinc 2 mg/day, and manganese 0.4 mg/day
vs. none
n = 80 ITT: yes Trace elements were administered during
the period on mechanical ventilation
Blinding: yes
(12)
Montoya 2009 [51] Medical/surgical septic C.Random: yes Day 1 IV sodium selenite 1000 μg , day 2
sodium selenite 500 μg, and thereafter
200 μg during 7 additional days vs. selenite
100 μg/day
ICU patients ITT: yes
n = 68 Blinding: double
(7)
Andrews 2011 [52] Mixed ICU, multicenter C.Random: yes 500 μg selenium supplemented PN (12.5 g
nitrogen, 2000 kcal) vs. standard PN (12.5 g
nitrogen, 2000 kcal) initiated after ICU
admission (actual median 2.6 days) for
7 days (actual duration, mean 4.1 days).
n = 502 ITT: yes
Blinding: double blind
(13)
Manzanares 2011 [53] Septic or trauma patients C.Random: not sure IV selenium supplementation loading dose
2000 μg (2 h) on day 1 followed by
1600 μg/day for 10 days vs. NaCl as placebon = 35 ITT: no (except mortality)
Blinding: single blind
(9)
Valenta 2011 [54] Patients with sepsis or SIRS C.Random: not sure IV selenium supplementation loading dose
1000 μg on day 1 followed by 500 μg/day
for 5–14 days + <75 μg/day of sodium
selenite added to PN vs. NaCl + <75 μg/day
of sodium selenite added to PN
n = 150 ITT: yes
Blinding: no
(8)
Heyland 2013 [16] Multicenter mixed ICUs C.Random: yes 500 μg selenium via PN + 300 μg selenium,
20 mg zinc, 10 mg β-carotene, 500 mg
vitamin E, 1500 mg vitamin C via EN vs.
placebo via PN and EN
n = 1218 ITT: yes
Blinding: double
(12)
Woth 2014 [14] Mixed ICU, severe septic patients with
multiorgan failure
C.Random: not sure 1000-μg/30 minutes loading dose of sodium
selenite and 1000-μg/day treatment for a
maximum of 14 days vs. control group
(not described)n = 40 ITT: yes
Blinding: no
(6)
Bloos 2016 [17] Multicenter mixed ICU patients with severe
sepsis or septic shock in last 24 h
C.Random: yes IV loading dose of 1000 μg sodium selenite
followed by continuous IV of 1000 μg
sodium selenite daily until ICU discharge or
for 21 days, whichever comes first vs.
placebo (NaCl)
ITT: yes
n = 1089 Blinding: double
(12)
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to 1.43, P = 0.58, I2 = 3 %). When the eight studies in
which researchers reported hospital LOS were aggregated,
there were no significant differences between the groups
(WMD −0.83, 95 % CI −3.71 to 2.04, P = 0.57, I2 = 0 %).
Also, when the eight studies in which researchers reported
ventilator days were aggregated, Se supplementation was
not associated with a reduction in MV days, although
significant heterogeneity was present (WMD −1.75, 95 %
CI −4.30 to 0.81, P = 0.18, I2 = 74 %, P value for test of
heterogeneity = 0.0004).
Overall effect on new renal dysfunction
After aggregating the data from eight RCTs in which re-
searchers reported new renal dysfunction, Se therapy was
not associated with a significant reduction in the incidence
of renal dysfunction (RR 0.79, 95 % CI 0.57–1.08, P = 0.14,
I2 = 0 %).
Subgroup analyses
PN selenium monotherapy vs. combined therapy
The RR associated with parenteral Se monotherapy for
mortality was 0.91 (95 % CI 0.79–1.04, P = 0.16; I2 = 12 %)
(Fig. 1), compared with 1.08 for studies in which re-
searchers used Se as part of combination therapy (95 % CI
0.93–1.25, P = 0.33). The test of subgroup differences was
not significant (P = 0.10). There was no effect on infec-
tions with either Se monotherapy or combined therapy
(test for subgroup differences, P = 0.59) (Fig. 2).
PN selenium loading dose vs. no loading dose
There was no treatment effect difference in mortality be-
tween studies in which researchers used a parenteral
loading dose of Se as an IV bolus (RR 0.90, 95 % CI
0.75–1.08, P = 0.30, I2 = 18 %) and those not using a
loading dose (RR 1.01, 95 % CI 0.90–1.14, P = 0.83)
(Fig. 3). The test for subgroup differences was not statis-
tically significant (P = 0.30). There was also no effect on
infectious complications in studies in which researchers
used a parenteral loading dose (RR 0.99, 95 % CI 0.90–
1.09, P = 0.84, I2 = 0 %), whereas there was a significant
reduction on infections in studies without a parenteral
Se loading dose (RR 0.87, 95 % CI 0.77–0.99, P = 0.03,
I2 = 0 %) (Fig. 4); the test for subgroup differences
was not significant (P = 0.11).
PN selenium high dose vs. low dose
There were no significant treatment effect differences in
mortality (test for subgroup differences P = 0.89) and in-
fections (test for subgroup differences P = 0.52) when we
compared studies with high-dose vs. low-dose parenteral
Se supplementation (data not shown).
Higher vs. lower mortality
The mean hospital mortality rate (or ICU mortality
when hospital mortality was not reported) in the control
group of all the trials was 33 %. After aggregating 11
studies with a higher mortality rate, we found that IV Se
did not have an effect on mortality (RR 0.94, 95 % CI
0.84–1.05, P = 0.26, I2 = 17 %). In addition, IV Se did not
have an effect on mortality in eight studies with a lower
mortality (RR 1.08, 95 % CI 0.90–1.08, P = 0.24, I2 = 0 %).
The test for subgroup differences was not significant
(P = 0.17) (see Additional file 2: Figure S2) In addition,
there were no significant treatment effect differences in
infections (test for subgroup differences P = 0.35) when
we compared studies with high vs. low mortality rates in
the control group (see Additional file 2: Figure S3).
Study quality on outcomes
When we evaluated study quality on outcomes, a statis-
tically significant effect of IV Se on the reduction of
mortality was found in the low-quality trials (RR 0.79,
95 % CI 0.66–0.94, P = 0.007, I2 = 0 %), whereas trials
with higher methodology scores did not show any
significant effect (RR 1.06, 95 % CI 0.95–1.19, P = 0.27,
heterogeneity I2 = 0 %). The overall tests for significance
revealed statistically significant differences between these
subgroups (P = 0.004) (see Additional file 3: Figure S4).
Neither high- nor low-quality trials demonstrated any
effect on infections (test for subgroup differences P =
0.72) (see Additional file 3: Figure S5).
Sepsis vs. nonsepsis studies
There was no effect of Se therapy on mortality in pa-
tients with sepsis (RR 0.92, 95 % CI 0.79–1.07, P = 0.27,
I2 = 10 %) or without sepsis (RR 1.03, 95 % CI 0.91–1.16,
P = 0.68; I2 = 0 %, test for subgroup differences P = 0.27).
However, there was a significant effect of parenteral Se
on the reduction of infections in RCTs of patients
Table 1 Randomized clinical trials evaluating selenium supplementation in critically ill patients (Continued)
Chelkeba 2015 [15] Mixed ICU patients with severe sepsis and
septic shock
C.Random: yes IV loading dose of 2000 μg sodium selenite
followed by continuous IV of 1500 μg
sodium selenite daily until day 14 vs.
standard therapy without seleniumn = 54 ITT: no
Blinding: single
(11)
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, COPD Chronic obstructive pulmonary disease, C.Random Concealed randomization,
D5W Dextrose 5 % in water, EN Enteral nutrition, ICU Intensive care unit, ITT Intention to treat, IV Intravenous, PN Parenteral nutrition, SIRS Systemic inflammatory
response syndrome, TBSA Total body surface area
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Table 2 Reported outcomes of included randomized clinical trials evaluating intravenous selenium supplementation in critically
ill patients
Study Mortality (%) Infections (%) LOS days
Experimental Control Experimental Control Experimental Control
Kuklinski 1991 [38] ICU 0/8 (0) ICU 8/9 ( 89) NR NR NR NR
Zimmerman 1997 [39] 3/20 (15) 8/20 (40) NR NR NR NR
Berger 1998 [40] 1/10 (10) 0/10 (0) 1.9 ± 0.9 (1–4) 3.1 ± 1.1 (2–5) ICU ICU
per patient per patient 30 ± 12 (10) 39 ± 13 (10)
Hospital Hospital
54 ± 27 (10) 66 ± 31 (10)
Angstwurm 1999 [41] Hospital Hospital NR NR NR NR
7/21 (33) 11/21 (52)
Porter 1999 [42] 0/9 (0) 0/9 (0) 5/9 (56) 8/9 (89) ICU ICU
22 ± 25.2 35.8 ± 21.9
Hospital Hospital
31.3 ± 23.4 49 ± 30
Berger 2001 [43] (a) Selenium alone 1/11 (9) (a) Selenium alone 5/11 (42) (a) ICU
2/9 (22) 5/9 (56) ICU 8.6 ± 8.1 (12)
(b) Selenium + zinc +
α-tocopherol
(b) Selenium + zinc +
α-tocopherol
8.0 ± 4.0 (9) Hospital
Hospital 64 ± 39 (12)
0/11 (0) 3/11 (27) 82 ± 78 (9)
(b)
ICU
5.8 ± 4.4 (11)
Hospital
60 ± 48 (11)
Linder 2004 [44] Not specified Not specified NA NA Hospital Hospital
5/32 (15.6) 3/35 (8.6) 24 (9–44) 26 (11–46)
Angstwurm 2007 [45] 28-day 28-day New infections (HAP) New infections (HAP) ICU ICU
46/116 (40) 61/122 (50) 10/116 (9) 10/122 (8) 15.1 ± 10 (116) 12.7 ± 9 (122)
Berger 2007 [46] 1/11 (9) 1/10 (10) 2.1 ± 1.0 3.6 ± 1.3 ICU ICU
per patient per patient 35 ± 27 (11) 47 ± 37 (10)
Forceville 2007 [47] 28-day 28-day Superinfection Superinfection ICU ICU
14/31 (45) 13/29 (45) 1/31 (3) 2/29 (7) 21 (7–40) 18 (10–31)
6-month 6-month Hospital Hospital
18/31 (59) 20/29 (68) 25 (7–68) 33 (11–51)
1-year 1-year
66 % 71 %
Mishra 2007 [48] ICU 8/18 (44) ICU 11/22 (61) 1.5 ± 1.9 1.8 ± 1.6 ICU ICU
Hospital Hospital per patient per patient 21.3 ± 16.2 (18) 20.8 ± 21.8 (18)
11/18 (61) 15/22 (68)
28-day 28-day
8/18 (44) 11/22 (50)
Berger 2008 [49] ICU ICU 36/102 (35) 34/98 (35) ICU ICU
8/102 (8) 5/98 (5) 5.8 ± 5.4 (102) 5.4 ± 5.7 (98)
Hospital Hospital Hospital Hospital
14/102 (14) 9/98 (11) 23 ± 20 (102) 26 ± 20 (98)
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Table 2 Reported outcomes of included randomized clinical trials evaluating intravenous selenium supplementation in critically
ill patients (Continued)
3-month 3-month
14/102 (14) 11/98 (11)
El-Attar 2009 [50] ICU ICU VAP VAP NR NR
2/40 (5.6) 1/40 (2.9) 5/36 (14) 7/34 (21)
Montoya 2009 [51] Hospital Hospital NR NR Hospital Hospital
6/34 (18) 8/34 (24) 12 (12–14) 17 (14–20)
Andrews 2011 [52] ICU ICU Confirmed Confirmed ICU ICU




6-month 6-month Hospital Hospital




Manzanares 2011 [53] ICU ICU VAP VAP ICU ICU
3/15 (20) 5/16 (31) 3/15 (20) 7/16 (44) 14 ± 11 (15) 13 ± 6 (16)
Hospital Hospital
5/15 (33) 7/16 (44)
Valenta 2011 [54] 28-day 28-day NR NR NR NR
19/75 (25) 24/75 (32)
Heyland 2013 [16] Hospital Hospital All All ICU ICU
216/617 (35) 199/601 (33) 168/617 (27) 181/601 (30) 14.2 ± 22.7 (617) 13.8 ± 23.1 (601)
14-day 14-day VAP VAP Hospital Hospital
154/617 (25) 132/601 (22) 71/617 (12) 95/601 (16) 31.2 ± 50.2 (617) 29.5 ± 44.8 (601)
28-day 28-day





Woth 2014 [14] In 14-day study period In 14-day study period Gram-negative Gram-negative NR NR
9/21 (43) 11/19 (58) 8/21 (38) 3/19 (16)
Gram-positive Gram-positive
3/21 (14) 2/19 (11)
Fungal Fungal
1/21 (5) 0/19 (0)





152/543 (28) 137/546 (25) 11 (5–22) 12 (6–24)
90-day 90-day 243/543 (44.7 %) 269/546 (49.3 %) Hospital Hospital




26 (16–42) 29 (17–50)
319/543 (58.8 %) 323/546 (59.2 %)
Chelkeba 2015 [15] 28-day 28-day VAP VAP ICU ICU
9/29 (31) 10/25 (40) 16/26 (61.5) 21/25 (84) 19.7 ± 11 (26) 23.8 ± 13 (25)
Hospital Hospital
25.2 ± 10 (26) 24.5 ± 9 (25)
Abbreviations: HAP Hospital-acquired pneumonia, ICU Intensive care unit, NA Nonattributable, NR Nonreported, , VAP Ventilator-associated pneumonia
Manzanares et al. Critical Care  (2016) 20:356 Page 8 of 16
without sepsis (RR 0.88, 95 % CI 0.78–0.99, P = 0.03,
I2 = 0 %) compared with trials of patients with sepsis
(RR 0.99, 95 % CI 0.90–1.10, P = 0.90, I2 = 0 %, test
for subgroup differences P = 0.12) (Fig. 5).
Effect of geographic representation of study patients on
outcomes
We found no significant treatment effect differences in
mortality (test for subgroup differences P = 0.33) and in-
fections (test for subgroup differences P = 0.57) when we
compared studies in which researchers administered IV
Se in North America vs. other geographic regions (see
Additional file 4: Figs. S6 and S7).
Publication bias
There was no indication that publication bias influenced
the observed aggregated results. In fact, funnel plots
were created for each study outcome, and the tests of
asymmetry showed a trend for mortality (P = 0.08),
although the data were not significant for overall
infections (P = 0.19), hospital LOS (P = 0.50), or MV days
(P = 0.37). However, the test for asymmetry was signifi-
cant for ICU LOS (P = 0. 047).
Discussion
This updated systematic review and meta-analysis of the
effects of parenteral Se as single or combined therapy on
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Fig. 1 Effects of selenium therapy on mortality: subgroup analysis of monotherapy vs. combined therapy. M-H Mantel-Haenszel
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clinical outcomes included 21 trials with a total of 4044
critically ill patients. Including the two largest recent
RCTs [16, 17], the main finding of our meta-analysis is
that there was a lack of treatment effect when critically
ill patients were treated with IV Se as single or com-
bined therapy. In fact, we were unable to demonstrate
any effect of IV Se supplementation on mortality or any
significant effect on infections, ventilator days, or ICU
and hospital LOS. Furthermore, our a priori defined sub-
group analyses did not show any treatment effects on
mortality. However, we found a significant effect of Se
therapy on infectious complications in those studies
without an initial IV loading dose, as well as a similar
effect in trials conducted in nonseptic patients.
Over the last few years, different meta-analyses of Se
supplementation in the critically ill have been published
[8–13]. The differences with our present review are due
largely to the variations in the studies included in the
reviews, as our systematic review and meta-analysis is
the first to include the two largest trials done to date on
Se therapy in the critically ill.
Our present findings do not support the concept of
pharmaconutrition by which micronutrients such as Se
are provided in high (i.e., supraphysiological) doses in
order to derive a pharmacological effect. Conversely to
previous findings regarding IV high-dose Se monother-
apy [8, 9], we did not find an overall effect of Se on
infectious complications in the critically ill, although
parenteral Se without an initial bolus significantly
reduced infections. Nonetheless, the overall point esti-
mate on infections of Se monotherapy is primarily and
largely influenced by the Bloos et al. [17] study, the
largest trial (n = 1089) (n= 1089) on pharmaconutrition
with high-dose Se monotherapy and PCT-guided anti-
biotic therapy in patients with severe sepsis and septic
shock. After giving an initial IV loading dose of 1000 μg
sodium selenite followed by a continuous infusion of
1000 μg sodium selenite daily for no longer than 21 days,
Bloos et al. [17] found that secondary infections were
similar in both groups of patients. Interestingly enough,
the SISPCT study [17] demonstrated that high-dose Se
supplementation had no therapeutic benefit in septic
patients, although plasma Se depletion at baseline was
restored to the normal range already by treatment day 1,
suggesting that correction of plasma Se concentration
may have no beneficial value. According to this study,
plasma Se levels in the Se or placebo groups were not
affected by allocation to the PCT guidance or non-PCT
Study or Subgroup
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Fig. 2 Effects of selenium therapy on infections: subgroup analysis of monotherapy vs. combined therapy. M-H Mantel-Haenszel
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guidance group. Our sensitivity analysis showed that,
after excluding the PCT guidance arm, the new RR was
0.95 (previous RR 0.98), which confirms that excluding
the PCT arm of the Bloos et al. study [17] did not affect
the overall result of our analysis.
In contrast to previous knowledge, we were unable to
find beneficial effects with daily doses higher than
500 μg or with providing an initial loading dose as an IV
bolus (usually 1000–2000 μg in 30 minutes to 2 h).
However, the absence of a significant test of subgroup
differences weakens any inferences drawn from this
subgroup analysis, but it likely shows the ineffectiveness
of employing a loading dose with an aim of improving
outcomes. So far, it has been proposed that a loading
dose of 1000–2000 μg Se as pentahydrate sodium selen-
ite has prooxidant and cytotoxic effects [1, 53, 55]. In a
previous pharmacokinetic study [31], it was demon-
strated that an initial IV bolus of 2000 μg followed by a
continuous infusion of 1600 μg/day was the most effect-
ive dose for returning serum Se to physiologic levels and
safely maximizing extracellular GPx activity and there-
fore the antioxidant capacity in critically ill patients.
According to current knowledge, a very high Se concen-
tration may be able to produce an inhibition of nuclear
factor-κB binding to DNA, controlling gene expression
and the synthesis of proinflammatory cytokines [56, 57],
and also may be able to induce apoptosis and cytotox-
icity in activated proinflammatory cells [58]. In addition,
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Fig. 3 Effects of selenium therapy on mortality: subgroup analysis of loading dose vs. no loading dose. M-H Mantel-Haenszel
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using an experimental model of sepsis, Wang et al. [59]
demonstrated that an IV Se bolus improved
hemodynamic status, decreased inflammation bio-
markers, and reduced mortality. Meanwhile, contrary to
our present data, in 2012 we found that a parenteral
loading dose showed a trend toward reduction in
mortality, whereas studies that did not use a bolus-loading
dose did not show any effect on mortality. Similarly,
Huang et al. [9], after aggregating nine RCTs on Se mono-
therapy, demonstrated that an IV bolus was associated
with a significant reduction in mortality (RR 0.73, 95 % CI
0.58–0.94, P = 0.01). However, neither of the previous
meta-analyses considered the SISPCT study [17].
So far, most clinical studies using Se at low doses
have been underpowered and have involved Se ad-
ministered in a cocktail approach. Thus, positive re-
sults in those trials cannot be clearly attributed solely
to Se supplementation. Notwithstanding this, accord-
ing to the concept of nutrient replacement, by which
micronutrient substitution is aimed at replenishing
losses and target restoration of physiological function
[60], Se must be supplemented at standard doses by
the enteral (77–100 μg/day) or the parenteral (100–
400 μg/day) route [61] because the results of our
meta-analysis do not refute previously recommended
Se substitution doses.
Despite earlier results of the Angstwurm study [41],
which demonstrated that IV high-dose Se substitution in
septic patients with an Acute Physiology and Chronic
Health Evaluation II score higher than 15 significantly
reduced the requirements of renal replacement therapy
(P = 0.035), the post hoc analysis of the REDOXS [16]
study demonstrated that patients with renal failure
might have a worse outcome when treated with high-
dose antioxidants. In fact, Heyland and coworkers [16]
demonstrated that both glutamine and antioxidants ap-
peared harmful in patients with baseline renal dysfunc-
tion, showing a higher 28-day mortality (OR 3.39, 95 %
CI 1.41–8.17, and 3.07, 95 % CI 1.24–7.59, for antioxi-
dants alone and glutamine plus antioxidants, respect-
ively). Nonetheless, in the recently published SISPCT
study [17], researchers did not find any risk of increased
harm in patients with baseline renal failure. In addition, in
the present study, we were unable to find any deleterious
effect of Se therapy on renal function in the critically ill.
Thus, the current understanding of why there is a lack
of therapeutic effect of IV Se therapy in critically ill
patients and patients with severe sepsis remains unclear.
Study or Subgroup
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Fig. 4 Effects of Selenium therapy on infections: subgroup analysis of loading dose vs. none. M-H Mantel-Haenszel
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Notwithstanding this, Se therapy could show benefits in
other patient populations that were not considered in
our meta-analysis. In fact, it is currently known that
circulating Se levels significantly decrease in the
perioperative period of cardiac surgery [62]. Also, in a
nonrandomized interventional trial, Stoppe et al. [63]
demonstrated that high-dose sodium selenite therapy as
a pharmaconutrient strategy was effective in preventing
the decrease of Se levels and that clinical outcomes may
be superior in supplemented patients compared with a
historical control group. The SodiUm SeleniTe
Administration IN Cardiac Surgery (SUSTAIN CSX®-
trial, ClinicalTrials.gov identifier NCT02002247), an
RCT aimed at evaluating the effects of perioperative
high-dose Se supplementation in high-risk cardiac surgi-
cal patients undergoing complicated open heart surgery,
is currently recruiting participants [64].
According to current evidence derived from recent
trials and our meta-analysis, the updated version of
Canadian Clinical Guidelines [65] recommended not
using IV Se alone or in combination with other antioxi-
dants in critically ill patients, which means that this
strategy has recently been downgraded.
The strength of our meta-analysis is based on the fact
that we used several methods to reduce bias (compre-
hensive literature search, duplicate data abstraction,
comprehensive search strategy using specific criteria,
and including non-English-language articles), we con-
tacted trial authors to obtain additional data and refine
our analysis, and we ultimately focused on clinically im-
portant primary outcomes in ICU patients. In addition,
given the wide variety of clinical diagnoses and the het-
erogeneous population of ICU patients included in this
systematic review (sepsis, septic shock, trauma, pancrea-
titis, surgical ICU patients), the results and conclusions
may be applied to a broad and heterogeneous group of
critically ill patients. While having a fairly large overall
sample size and low heterogeneity, which makes the esti-
mate quite robust, our subgroup analyses are limited by
the small number of trials.
Conclusions
In this updated systematic review and meta-analysis, we
found that parenteral Se as single or combined therapy
with other antioxidant micronutrients had no effect on
mortality, infections, renal function, ICU and hospital
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Fig. 5 Effects of selenium therapy on infections: sepsis vs. non sepsis studies. M-H Mantel-Haenszel
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LOS, or ventilator days. Moreover, subgroup analyses
did not show any treatment effects on mortality,
although a significant effect on infections was found in
those studies performed in nonseptic patients and when
high-dose Se as an initial IV bolus was not administered.
According to our findings, IV Se therapy cannot be
recommended for routine clinical use in critically ill
patients. In view of these results, we suggest that we
need to go back to basics and obtain more pharmacoki-
netic and pharmacodynamic data in specific patient
populations with specific dosing strategies. We strongly
believe that, without this first step exploring pharmaco-
kinetic data, no further research on parenteral Se mono-
therapy in critically ill patients is warranted.
Key messages
 Se is an essential trace element with antioxidant,
immunomodulatory, and anti-inflammatory effects
that has been considered the cornerstone of the
antioxidant defense system.
 Recently, in the largest trial on IV Se monotherapy,
investigators were unable to find any clinical benefit
of high-dose sodium selenite in patients with sepsis
and septic shock.
 According to our findings, there is no evidence for a
beneficial effect on mortality, infections, and other
relevant clinical outcomes of high-dose IV Se as sin-
gle or combined therapy (antioxidant cocktails) in
critically ill patients.
 IV Se may be able to significantly reduce infections
in those studies performed with nonseptic patients
and when high-dose Se as an initial IV bolus is not
administered.
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